p53 Selective and Nonselective Replication of an E1B-deleted Adenovirus in Hepatocellular Carcinoma[1]

Charles M. Vollmer, Antoni Ribas,[2] Lisa H. Butterfield, Vivian B. Dissette, Kahlil J. Andrews, Fritz C. Eilber, Lara D. Montejo, Angela Y. Chen, Billy Hu, John A. Glaspy, William H. McBride, and James S. Economou[3]

Divisions of Surgical Oncology [C. M. V., A. R., L. H. B., V. B. D., K. J. A., F. C. E., L. D. M., A. Y. C., B. H., J. S. E.], Hematology/Oncology [A. R., J. A. G.], and Experimental Radiation Oncology [W. H. M.], University of California Los Angeles, Los Angeles, California 90095-1782

ABSTRACT

An E1B gene-attenuated adenovirus (*dl*1520) has been proposed to have a selective cytolytic activity in cancer cells with a mutation or deletion in the p53 tumor suppressor gene (p53-null), a defect present in almost half of human hepatocellular carcinomas (HCCs). In this study, the *in vitro* and *in vivo* antitumor activity of *dl*1520 was investigated focusing on two human HCC cell lines, a p53-wild type (p53-wt) cell line and a p53-null cell line. *dl*1520 was tested for *in vitro* cytopathic effects and viral replication in the human HCC cell lines Hep3B (p53-null) and HepG2 (p53-wt). The *in vivo* antitumor effects of *dl*1520 were investigated in tumors grown s.c. in a severe combined immunodeficient mouse model. In addition, the combination of *dl*1520 infection with systemic chemotherapy was assessed in these tumor xenografts. At low multiplicities of infection, *dl*1520 had an apparent p53-dependent *in vitro* viral growth in HCC cell lines. At higher multiplicities of infection, *dl*1520 viral replication was independent of the p53 status of the target cells. *In vivo*, *dl*1520 significantly retarded the growth of the p53-null Hep3B xenografts, an effect augmented by the addition of cisplatin. However, complete tumor regressions were rare, and most tumors eventually grew progressively. *dl*1520 had no effect on the *in vivo* growth of the p53-wt HepG2 cells, with or without cisplatin treatment. The E1B-deleted adenoviral vector *dl*1520 has an apparent p53-dependent effect in HCC cell lines. However, this effect is lost at higher viral doses and only induces partial tumor regressions without tumor cures in a human HCC xenograft model.

INTRODUCTION

HCC[4] is the most common cause of cancer death worldwide (1). Surgical resection or liver transplantation provide long-term disease-free remissions, but only a minority of patients are candidates for these treatments (2). Furthermore, recurrence rates for those who undergo resection approach 70% (3). Therefore, the great majority of HCC patients will ultimately die of their disease. Homozygous mutations or deletions of *p53*, a tumor suppressor gene that encodes a nuclear phosphoprotein that is a key regulator of the cell cycle (5), have been reported in 30–50% of HCCs (4). Mutant p53 correlates with tumor dedifferentiation, metastatic potential, and other poor prognostic indicators such as capsular invasion and portal vein involvement (6).

The adenoviral E1B M_r 55,000 gene product is capable of binding to and inactivating the p53 gene product (7, 8), thereby enabling the virus to overcome restrictions imposed on viral replication by the host cell cycle. In hosts with tumors carrying *p53* mutations, a wt AdV will have a replication advantage in the *p53*-mutated tumor cells but will have difficulty replicating in p53-wt normal cells (due to the p53 block). If the AdV is modified to lack expression of the E1B M_r 55,000 protein, it will maintain its ability to replicate in p53-null tumor cells while having further difficulty replicating in p53-wt normal cells (the effect of p53 will not be blocked by the AdV E1B gene product). Barker and Berk (9) constructed one such virus (*dl*1520), and its *in vitro* and *in vivo* effects on p53-wt and p53-null cell lines have been analyzed by Bischoff *et al.* (10) and Heise *et al.* (11). Results from these studies suggest that *dl*1520 replicates more efficiently in cells lacking a functional *p53* gene. When tested *in vivo,* this virus was able to eradicate p53-null tumors, supporting a selective growth advantage in cells lacking functional p53. This hypothesis has been recently challenged by Hall *et al.* (12), who have suggested that functional p53 is required for *dl*1520 replication. Based on these conflicting reports, we tested the effects of *dl*1520 in several cell lines to determine whether this vector has a selective tumor cytotoxic effect capable of treating p53-null liver cancers. Our data suggest a viral dose-dependent effect rather than a p53-selective effect of *dl*1520 in p53-wt and p53-null HCC cell lines.

MATERIALS AND METHODS

Mice and Cell Lines. Male 6–9-week-old CB17 Beige SCID mice were bred and housed in a controlled pathogen environment at the Experimental Radiation Oncology Animal Facility at the UCLA. All animal studies were conducted in accordance with the UCLA Animal Care Policy as prescribed by the Chancellor's Animal Research Committee. Hep3B and HepG2 are well-characterized human HCC cell lines (13), whereas HeLa and C33A are human cervical carcinoma cell lines. Hep3B, HepG2, and HeLa were obtained from American Type Culture Collection (Manassas, VA). C33A was provided by Dr. Arnold Berk (UCLA). All four cell lines were maintained as monolayers and serially passaged in culture in RPMI 1640 containing 10% FCS (Gemini Products, Calabasas, CA) and 1% (v/v) penicillin, streptomycin, and fungizone (Gemini; complete media) and incubated at 37°C in 5% CO_2. Human embryonal kidney 293 cells, provided by Dr. Kohnosuke Mitani (UCLA), were passaged similarly in DMEM. Tumors for *in vivo* studies were maintained through serial passage in SCID mice as described previously (14).

Assessment of p53 Status. The p53 status of Hep3B, HepG2, and HeLa tumor cell lines, which is already well documented (15–17), was reconfirmed using a Human *p53* Amplifier Panel (Clontech, Palo Alto, CA) according to the manufacturer's instructions. DNA from cultured cells was subjected to the PCR and found to be as reported: HepG2 and HeLa were found to be positive for all exons examined (2–3, 5–11); whereas Hep3B was deleted in exons 8–11. The human cervical carcinoma C33A contains an inactivating mutation of the *p53* gene at codon 273 (18).

Viruses. *dl*1520 and Ad5 (wt AdV5) were kind gifts of Dr. Arnold Berk (UCLA). *dl*1520 is a E1B double mutant human group C chimera (Ad2 and Ad5) in which a deletion of nucleotides 2496–3323 and a C to T transition at position 2022 render the E1B M_r 55,000 gene product functionally inactive (9). AdV-Luc (generously provided by Dr. Michael Barry; University of Texas-Southwestern, Dallas, TX) is a replication-incompetent, E1 region-deleted type-5 AdV that contains the firefly *Photinus pyralis* luciferase reporter gene

under the transcriptional control of the cytomegalovirus promoter (14, 19). Working stocks of virus were grown on 293 human embryonal kidney cells, purified on a CsCl gradient, and titered on 293 cells (19).

***In Vitro* CPE Assays.** Cultured cells were added to 34-mm wells at a concentration of 3×10^5 cells/well. Cultures were transduced 16 h later in AdV infection media (RPMI 1640 + 2% FCS) with *dl*1520, AdV-Luc, or wt AdV for 2 h at various MOIs. Cells were then washed with PBS, incubated at 37°C, and observed daily for a CPE by the wt AdV at a MOI of 0.1 (which served as a positive control for viral replication). Once this effect was demonstrated (usually between days 4 and 9, depending on the individual cell culture), the cells were fixed and stained with 10% formalin/crystal violet solution.

Colorimetric Cell Viability Assay. A colorimetric assay using tetrazolium and MTT (Sigma, St. Louis, MO) was used to assess cell viability after viral infection. Cells were infected at various MOIs of wt AdV or *dl*1520 for 2 h at 37°C. Uninfected cells served as controls. After infection, cells were washed with PBS and placed, in triplicate, in a 96-well plate at a concentration of 1×10^3 cells/well in 200 μl of complete growth media. Eight days later, 25 μl of MTT (4 mg/ml) were added to each well and incubated at 37°C for 4 h. Plates were centrifuged at $500 \times g$ for 5 min, and the medium was aspirated with care so as not to disturb the formazen crystals at the bottom of the well. DMSO (100 μl) was added to each well to solubilize the crystals. Plates were read at $A_{600 \text{ nm}}$ on a scanning multiwell spectrophotometer (Bio-Rad, Hercules, CA). Results are reported as the percentage of absorbance of uninfected control cells.

***In Vitro* Viral Replication Assay.** Cells were plated in 6-well plates at a concentration of 4×10^5 cells/well. Sixteen h later, the cellular monolayers were washed with PBS and infected with virus at a MOI of 5 in 0.75 ml of AdV infection media at 37°C for 90 min. After removal of the unadsorbed virus, the monolayers were washed once with PBS and incubated at 37°C for different periods of time in reduced serum (5%) growth media. Plates corresponding to individual time points were subsequently frozen at −80°C. Lysates were prepared by three cycles of freezing and thawing. Serial dilutions were subsequently titered on 293 human embryonic kidney cells.

***In Vivo* Tumor Model.** Progressively growing tumors were passaged *in vivo* as described previously (14). When tumors reached an average diameter of 4–6 mm, mice were randomly allocated to various treatment groups. Intratumoral dosing regiments varied with each particular study, ranging from a total dose of 1×10^9 to 6×10^9 pfu/tumor, applied over 3–5 consecutive days. In most experiments, three doses at 2×10^9 pfu/tumor of either *dl*1520, AdV-LUC, or wt AdV were injected in 100 μl of PBS vehicle (evenly distributed in all four quadrants of the tumor). For studies combining virus and chemotherapy, 2×10^9 pfu of *dl*1520 were injected intratumorally for 3 consecutive days, followed by i.p. administration of cisplatin [*cis*-diamminedichloroplatinum(II); 4 mg/kg] every other day over the ensuing 6 days. Tumor growth was monitored twice weekly using a caliper. Tumor volume was estimated using the following formula: volume = $\frac{4}{3}\pi r^3$.

Statisical Analysis. Student's *t* test or the rank-sum test (if failing the Kolmogorov-Smirnov test for normality) was performed to interpret the significance between final tumor volumes of animals treated with *dl*1520 and those treated with other therapies. Two-sided *P*s reflect individual comparisons.

RESULTS

***In Vitro* Effects of *dl*1520 on p53-wt and p53-null HCC Cell Lines.** The CPE of *dl*1520 on the HCC cell lines HepG2 (p53-wt) and Hep3B (p53-null) was examined. The p53-wt cell line HeLa and the *p53*-mutated human cervical carcinoma (C33A) were used as negative and positive controls, respectively. The effect of *dl*1520 was compared to a wt AdV (expected to lyse all cell lines) and a replication-incompetent E1-deleted AdV (AdV-Luc, which was expected to be nonreplicative and nonlytic in all cell lines except 293 cells). Results of a crystal violet CPE assay are presented in Fig. 1. The wt AdV completely lysed all cell types even at a MOI of 0.1, corresponding to 1 viral particle for every 10 tumor cells, suggestive of active viral replication and a CPE leading to complete cell lysis. The E1-deleted AdV-Luc vector only displayed a CPE on the permissive 293 cells

that express E1 gene products *in trans*. *dl*1520 had different effects in the tested cell lines. It lysed 293 cells, consistent with the presence of the E1 gene products including the E1B M_r 55,000 protein, enabling effective viral replication. It lysed the two p53-null lines, the cervical carcinoma C33A and the HCC line Hep3B, at a MOI of 0.01–0.1, suggestive of active viral replication. This effect was not noted in the p53-wt cell lines HeLa and HepG2 at a MOI of 0.1. However, the HepG2 culture was completely lysed at a MOI of 1. In an MTT assay, *dl*1520 also displayed a higher CPE on the two p53-null cell lines tested (Fig. 2). To achieve a similar decrease in cell colonies, *dl*1520 had to be added at a MOI of at least 1 to the p53-wt cell lines HeLa and HepG2. Taken together, the observed effects of low viral multiplicity of *dl*1520 on the HCC cell lines correspond to 1–2-log difference in cytopathic efficacy for the p53-null Hep3B in both the qualitative crystal violet CPE assay and the more quantitative MTT chromogenic assay. This differential effect decreases or disappears when a higher MOI is used.

***dl*1520 Reproductive Cycle in p53-wt and p53-null HCC.** The adenoviral reproductive cycle in target cells was studied using a one-step growth curve assay (Fig. 3). In this assay, the infectious process is initiated at high viral concentrations (MOI, 5), which ensures a rapid, nearly synchronous infection in all target cells. To eliminate unadsorbed virus, cultures were washed after AdV infection. Then, at various times after the initiation of infection, culture samples were tested for infective virus levels on a plaque assay in 293 cells as described in "Materials and Methods." The wt AdV shows a viral replication curve in the three tested cell lines. This viral growth curve consists of an initial adsorption period, an eclipse period when no infective viral particles can be recovered from the culture, and a virus release or burst period, when the virions are released from the infected cells and can be titrated in a plaque assay. The E1-deleted replication-defective vector AdV-Luc demonstrates a nonreplicative viral cycle in all three cell lines. After viral adsorption, AdV-Luc viral particles cannot reassemble and generate new infective virions due to the absence of the E1 gene products. The viral reproductive cycle of *dl*1520 was tested on one p53-null cell line (Hep3B) and two p53-wt cell lines (HeLa and HepG2). The viral growth curve of *dl*1520 on Hep3B cells was nearly equivalent to that of the wt AdV, suggesting that the absence of *E1B* genes in *dl*1520 did not hamper its ability to replicate in this p53-null HCC cell line. As originally described by Barker and Berk (9), *dl*1520 infection of the cervical carcinoma line HeLa generates a 2-log lower growth curve compared to the growth curve of wt AdV in this cell line, suggesting a somewhat defective growth of *dl*1520 in HeLa cells. However, *dl*1520 generated an effective replicative growth curve in the other p53-wt cell line. As observed in the CPE assays (Figs. 1 and 2), infection of HepG2 with *dl*1520 at a MOI greater than 0.1 generates a viral growth cycle with similar kinetics to wt AdV in this p53-wt HCC cell line. In conclusion, at a sufficiently high MOI, *dl*1520 replicates at a similar rate in p53-null and p53-wt HCC cell lines.

***In Vivo* Antitumor Activity of *dl*1520 in Human HCC Xenografts.** The antitumor effects of repeated intratumoral injections with *dl*1520 were studied in two human HCC xenografts: (*a*) Hep3B (p53-null); and (*b*) HepG2 (p53-wt). *dl*1520 was administered at doses ranging from $1–6 \times 10^9$ pfu/injection to mice with tumors with mean diameters of 4–6 mm, whereas randomly allocated control mice received injections with PBS. Intratumoral injection of *dl*1520 into the p53-wt HepG2 cells did not alter tumor growth in a total of eight studies using 34 mice with HepG2 tumors (Fig. 4*a*). No growth retardation was observed in PBS-treated tumors. In contrast, *dl*1520 resulted in significant tumor growth retardation in nine studies in which 39 mice with Hep3B tumors (p53-null) were treated with *dl*1520; again, no responses were seen in the PBS-treated mice (Fig.

4370

Fig. 1. *In vitro* CPE of *E1*-deleted, *E1B*-deleted, and wt AdV. Cultured cells (*A*, 293; *B*, HeLa; *C*, C33A; *D*, Hep G2; *E*, Hep 3B) were transduced with either *dl*1520, AdV-Luc, wt AdV, or no virus (cells alone) for 2 h at the indicated MOI. Cells were washed to remove residual virus, returned to incubation in culture media, and followed daily for a demonstrable CPE by the wt AdV at a MOI of 0.1. This occurred from day 4–9, depending on the individual cell line (293 cells took the shortest time to display a CPE; HeLa cells took the longest time to display a CPE). At that time, supernatants were aspirated, and the remaining adherent cells were fixed in 1% paraformaldehyde/PBS solution, stained with crystal violet solution, and washed extensively with PBS.

4*b*). However, complete tumor regression was rare (observed only in one animal), and tumors ultimately grew progressively, despite repeated *dl*1520 treatment (data not shown).

The *in vivo* effect of *dl*1520 was compared to the wt AdV and the

Fig. 2. Colorimetric cell viability assay after *dl*1520 infection at escalating MOIs. Cultured cells were infected at the indicated MOIs with either *dl*1520, wt AdV, or no virus (controls) for 2 h. After washing with PBS to remove unadsorbed virus, cells were plated (in triplicate) at 1×10^3 cells/well in a 96-well plate. Eight days later, MTT (4 mg/ml) was added and incubated for 4 h, and the results were determined at $A_{600\,nm}$ in a scanning spectrophotometer. Results are reported as the percentage of absorbance of controls where 100% equals viability (after 8 days of culture) of uninfected control cells for each particular cell line tested.

E1-deleted AdV-Luc (Fig. 5). Significant tumor growth inhibition of Hep3B was observed with either *dl*1520 ($P = 0.01$) or wt AdV ($P = 0.02$) treatment, whereas the tumor growth curve was only slightly diminished by administration of AdV-Luc ($P = 0.4$). In HepG2 cells, wt AdV significantly altered the tumor growth when compared with saline-injected controls (data not shown), whereas *dl*1520 repeatedly showed no effects, ruling out the possibility that the lack of *in vivo* effect of *dl*1520 in this tumor is an inherent defect of *in vivo* AdV replication. In conclusion, *dl*1520 significantly retards the growth of a p53-null HCC xenograft but has no effect on the growth of a p53-wt HCC xenograft.

***dl*1520 and Chemotherapy Have Additive Antitumor Effects.** The combination of *dl*1520 with the chemotherapeutic agent cisplatin, which has moderate efficacy for human HCC, was investigated. When compared to saline-injected controls, single-agent therapy with either intratumoral *dl*1520 ($P = 0.003$) or systemic chemotherapy ($P = 0.007$) displayed equivalent growth retardation. Combined treatment with *dl*1520 followed by cisplatin demonstrated markedly improved antitumor effects when compared to treatment with either *dl*1520 or cisplatin alone (Fig. 6*a*). Four of five tumors in the combined therapy group initially regressed, whereas the fifth tumor stabilized. Although some tumors in this group displayed a transient complete response, eventual tumor outgrowth occurred in all five tumors. In contrast, the addition of *dl*1520 to cisplatin treatment of HepG2 tumors did not improve the antitumor effect of cisplatin alone (Fig. 6*b*).

4371

Fig. 3. Viral replication in cultured human HCC cells Hep3B (p53-null) and HepG2 (p53-wt). HeLa cervical carcinoma cells serve as a p53-wt, non-HCC comparison. The viral growth curves illustrated were generated after infection with *dl*1520, wt AdV, or the replication-incompetent AdV-Luc at a MOI of 5. After a 90-min infection, cells were washed with PBS, incubated at 37°C in 5% complete media, and frozen at various time points. After three freeze/thaw cycles, the viral content of the lysates was titered on a 293 plaque assay. Data were consistent in two replicate studies.

DISCUSSION

AdVs are DNA viruses that cause limited pathology in humans, mainly conjunctivitis and flu-like syndromes. Their life cycle consists of: (*a*) an adsorption and viral entry into the host cells, when the viral capsid interacts with the Coxsackie and AdV receptor on the target cell membrane (20); (*b*) an eclipse period, when viral particles are nondetectable in the infected cells because they disintegrate and use the host's cell replication machinery to synthesize their own DNA, mRNA, and proteins; and (*c*) the assembly and burst period, when multiple virions assemble in the cytoplasm and eventually lyse the host cell to infect neighboring cells. As vehicles for gene therapy strategies, AdVs are rendered replication incompetent by disruption of the *E1* region, which encodes early proteins required for the synthesis of new viral DNA. The cDNA of the gene of interest to be used in gene therapy strategies is placed in the empty AdV *E1* region. This results in viral particles capable of infecting a single host cell, where they produce mRNA of the inserted gene, but the eclipse period stops before the production of new viral particles because the *E1* gene products are not synthesized. To allow viral particle assembly, the 293 cell line was constructed (21). This cell line, derived from a human embryonal kidney cancer line, was stably transfected with the AdV *E1* gene. Therefore, when *E1*-deleted AdV vectors infect 293 cells, they will generate infective viral particles because all viral products will be synthesized in the host cells.

AdV *E1* consists of two regions, *E1A* and *E1B*. *dl*1520 was originally constructed by Barker and Berk (9) to study the function of the *E1B* genes. They demonstrated that the *E1B* gene region has a critical function in AdV replication because it encodes proteins that dysregulate normal cell growth to the advantage of viral replication. One of its

products, the M_r 55,000 protein, binds and inactivates the *p53* gene product in the infected cells. If the *E1B* gene is not expressed by the AdV, replication does not proceed because the p53 protein detects a malfunction in the cell's replication cycle and drives its machinery to cell cycle arrest or apoptosis. However, when the *E1B* region is expressed by the infecting AdV particles, it will bind to p53 and inactivate it. This allows the virus to use the host cell replication machinery to generate multiple viral particles and ultimately lyse the cell (7, 8, 17).


Fig. 4. *In vivo* growth of human HCC after treatment with *dl*1520. The 4–6-mm HepG2 (p53-wt; *a*) and Hep3B (p53-null; *b*) tumors in C17/Beige SCID mice were treated intratumorally with 2×10^8 pfu of *dl*1520 for 5 consecutive days (as indicated by *arrows*; days 21–25 for Hep3B and days 14–18 for HepG2) in 100 μl of PBS. Control mice received an equivalent volume of intratumoral PBS. Significant tumor growth inhibition was evident by day 22 after initiation of therapy for Hep3B cells ($P < 0.0001$), but not for HepG2 cells ($P = 0.8$ at day 20 after initiation). Data are presented as the mean tumor volume ± SE.

4372

Fig. 5. Comparison of the *in vivo* growth of Hep3B tumors after treatment with *dl*1520, wt AdV, and AdV-Luc. Tumors established in C17/Beige SCID mice were treated intratumorally three times (every other day over days 28–32, as indicated by *arrows*) with either *dl*1520, wt AdV, or the replication-incompetent AdV-Luc at 2×10^9 pfu in 100 μl of PBS. By day 50, a significant growth inhibition was observed in those mice treated with *dl*1520 ($P = 0.01$) and wt AdV ($P = 0.02$) but not in those treated with AdV-Luc ($P = 0.4$) when compared to the progressive growth of the control group. Data are presented as the mean tumor volume $\pm$ SE and are indicative of one of two such experiments with a similar outcome.

Bischoff *et al.* (10) investigated the effects of *dl*1520 infection on p53-null cancer cells. Theoretically, *dl*1520 would replicate in these cells because p53 is not present to prevent viral replication. This would generate a replication-competent environment in which the *E1B*-deleted AdV could produce multiple viral particles that would lyse the p53-null target cells. However, if these viral particles infected p53-wt cells, viral replication would not proceed. Therefore, these investigators (10) used *dl*1520 to infect a panel of p53-wt and p53-null cell lines both *in vitro* and *in vivo*. Their results using cervical carcinoma and glioblastoma cell lines suggest that *dl*1520 replicates 100 times more efficiently in cells lacking functional p53. However, when testing was extended to additional cell lines, this selective growth was not supported. *dl*1520 demonstrated a CPE in 7 of 10 p53-wt cell lines (including HepG2) tested (11). Furthermore, there is evidence that, in certain situations, p53-wt plays a necessary role in mediating cellular destruction to allow a productive AdV infection (12).

There is no effective systemic treatment for HCC (1–3). Because most human HCC tumors have mutations or deletions in the *p53* gene (4), we tested the activity of *dl*1520 in this disease. Moreover, AdV vectors have been shown to selectively target the liver following any route of administration (14, 19). Our *in vivo* data suggest that *dl*1520 may exert p53-dependent growth inhibition in human HCC xenografts propagated in SCID mice. *In vivo* inhibition of tumor growth was not curative, despite repeated virus administration. Also, when directly compared with p53 replacement gene therapy, the *in vivo* effect of *dl*1520 was fairly comparable and was certainly no better.[5] In our immunodeficient mice, which are unable to mount antibody or cellular immune responses to repeated viral exposure, tumor escape after *dl*1520 injection suggests an acquired resistance to AdV infection, a

change in killing susceptibility of tumor cells, or a lack of adequate viral distribution in the tumors. These possibilities were not studied by us. *In vivo* efficacy of *dl*1520 treatment could be enhanced with concomitant cisplatin therapy; however, it was not a goal of this study to optimize this combined therapy.


Fig. 6. Additive effects of chemotherapy and *dl*1520. *a*, mice (five mice/group) harboring the p53-null Hep3B tumor were treated with intratumoral *dl*1520 at 2×10^9 pfu in 100 μl of PBS for 3 consecutive days (days 27–29, as indicated by *arrows*); i.p. cisplatin at 4 mg/kg on days 31, 33, and 35; *dl*1520 followed by cisplatin; or intratumoral PBS (controls). At day 45, a significant reduction in the growth rate is seen by both singular therapies (*dl*1520, $P = 0.003$; cisplatin, $P = 0.0007$) as well as by the combination therapy ($P < 0.0001$) when compared to progressively growing controls. In addition, the combination of *dl*1520 followed by cisplatin was significantly better when compared to either individual therapy ($P = 0.01$ *versus* cisplatin alone; $P = 0.02$ *versus* *dl*1520 alone). *b*, mice (five mice/group) bearing the p53 intact HepG2 tumor were treated as described in *a* except that *dl*1520 treatment occurred on days 19–21 (*arrows*), and cisplatin treatment followed on days 23, 25, and 27. When compared with the PBS-injected controls, cisplatin, alone and in conjunction with *dl*1520, showed a significantly altered growth curve ($P = 0.004$ and $P = 0.05$, respectively). No difference was observed with *dl*1520 alone ($P = 0.5$). In addition, there was not a significant difference when comparing the combined therapy group with the group treated with cisplatin alone ($P = 0.4$).

---

[5] Unpublished observations.

4373

A wide range of *dl*1520 viral doses could not be tested *in vivo* because most mice died after an intratumoral injection of 5×10^9 pfu. Therefore, we used *in vitro* CPE testing and viral growth curve assays over a wide MOI range. In these studies, the apparent p53 selectivity was lost, suggesting that other factors play a role in *dl*1520 biology (11, 17). In the original description of *dl*1520, Barker and Berk (9) demonstrated that this vector replicated in p53-wt HeLa cells in a viral dose-dependent manner, generating viral growth curves superimposable to ours. Further testing of *dl*1520 in HeLa cells by Goodrum and Ornelles (17) suggests that the E1B M_r 55,000 protein functions directly in overcoming the growth restrictions imposed on viral replication by the cell cycle in a mechanism that is p53-independent. In their extensive studies, HeLa cells were synchronized to S phase or G_1. Compared to cells infected in G_1, cells in S phase infected with *dl*1520 had a greater number of infectious centers, produced higher levels of virus progeny, and demonstrated a near wt CPE. Therefore, *dl*1520 has acquired a dependence on the cell cycle for virus progeny production and replicates in cells in S phase. Taken together with our data, when sufficient *dl*1520 viral particles are delivered and sufficient target cells are in S phase, *dl*1520 may replicate regardless of the p53 status. The presence of contaminating wt replication-competent virus would be an alternative explanation for the loss of p53 selectivity *in vitro*. Although it is certainly possible that our *dl*1520 may be contaminated with replication-competent virus, the similarity of our viral growth curves and the ones from Baker and Berk (9) and Goodrum and Ornelles (17) tested in the same cell line (HeLa) argue against their presence.

Our *in vivo* data cannot be translated directly to a clinical setting. We used immunodeficient mice that have a greatly diminished ability to block viral replication. This may allow for greater viral replication and corresponding tumor lysis in this animal model. The great majority of adult humans have antiadenoviral-neutralizing antibodies, which might limit the effectiveness of this treatment approach. Furthermore, AdVs infect human cells more easily than murine cells (21). Therefore, *dl*1520 would have a selective advantage in lysing human cancers in our SCID mouse model without generating active infection in the mouse. In conclusion, treatment of p53-null HCC with the E1B-deleted *dl*1520 vector generates permissive viral replication sufficient to lyse p53-null cells *in vivo*. However, this response is a function of viral dose and schedule and is not entirely dependent on the p53 status of the tumor.

ACKNOWLEDGMENTS

REFERENCES

1. Venook, A. P. Treatment of hepatocellular carcinoma: too many options? J. Clin. Oncol., *12:* 1323–1334, 1994.
2. Levin, B., and Amos, C. Therapy of unresectable hepatocellular carcinoma. N. Engl. J. Med., *332:* 1294–1296, 1995.
3. Sugioka, A., Tsuzuki, T., and Kanai, T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery (St. Louis), *113:* 612–618, 1993.
4. Tabor, E. Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J. Med. Virol., *42:* 357–365, 1994.
5. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumour suppressor gene. Nature (Lond.), *351:* 453–456, 1991.
6. Okuda, T., Hirohashi, K., Kinoshita, H., Wakasa, K., and Sakurai, M. Characteristic histologic features of human hepatocellular carcinoma with mutant p53 protein. World J. Surg., *20:* 215–220, 1996.
7. Sarnow, P., Ho, Y. S., Williams, J., and Levine, A. J. Adenovirus E1b–58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell, *28:* 387–394, 1982.
8. Yew, P. R., and Berk, A. J. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature (Lond.), *357:* 82–85, 1992.
9. Barker, D. D., and Berk, A. J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology, *156:* 107–121, 1987.
10. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Washington DC), *274:* 373–376, 1996.
11. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., *3:* 639–645, 1997.
12. Hall, A. R., Dix, B. R., O'Carroll, S. J., and Braithwaite, A. W. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat. Med., *4:* 1068–1072, 1998.
13. Aden, D. P., Fogel, A., Plotkin, S., Damjanov, I., and Knowles, B. B. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature (Lond.), *282:* 615–616, 1979.
14. Bui, L. A., Butterfield, L. H., Kim, J. Y., Ribas, A., Seu, P., Lau, R., Glaspy, J. A., McBride, W. H., and Economou, J. S. *In vivo* therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum. Gene Ther., *8:* 2173–2182, 1997.
15. Bressac, B., Galvin, K. M., Liang, T. J., Isselbacher, K. J., Wands, J. R., and Ozturk, M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA, *87:* 1973–1977, 1990.
16. Hsu, I. C., Tokiwa, T., Bennett, W., Metcalf, R. A., Welsh, J. A., Sun, T., and Harris, C. C. *p53* gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis (Lond.), *14:* 987–992, 1993.
17. Goodrum, F. D., and Ornelles, D. A. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J. Virol., *71:* 548–561, 1997.
18. Scheffner, M., Munger, K., Byrne, J. C., and Howley, P. M. The state of the *p53* and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA, *88:* 5523–5527, 1991.
19. Toloza, E. M., Hunt, K., Swisher, S., McBride, W., Lau, R., Pang, S., Rhoades, K., Drake, T., Belldegrun, A., Glaspy, J., and Economou, J. S. *In vivo* cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther., *3:* 11–17, 1996.
20. Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., and Finberg, R. W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (Washington DC), *275:* 1320–1323, 1997.
21. Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol., *36:* 59–74, 1977.

p53 Selective and Nonselective Replication of an E1B-deleted Adenovirus in Hepatocellular Carcinoma

Charles M. Vollmer, Antoni Ribas, Lisa H. Butterfield, et al.

Updated version	Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/59/17/4369

Cited articles	This article cites 21 articles, 6 of which you can access for free at: http://cancerres.aacrjournals.org/content/59/17/4369.full#ref-list-1
Citing articles	This article has been cited by 12 HighWire-hosted articles. Access the articles at: http://cancerres.aacrjournals.org/content/59/17/4369.full#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/59/17/4369. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.